Syndax Pharmaceuticals, Inc. (SNDX) vs Stoke Therapeutics, Inc. (STOK)
A side-by-side comparison of Syndax Pharmaceuticals, Inc. and Stoke Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SNDX
Syndax Pharmaceuticals, Inc.
$17.38HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
STOK
Stoke Therapeutics, Inc.
$24.30HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
Total return — SNDX vs STOK
growth of $100 · dividends reinvested · last 7ySNDX +105.4% (+10.8%/yr)STOK -1.0% (-0.1%/yr)SNDX compounded faster over this window
SNDX STOK
SNDX vs STOK: by the numbers
- •STOK is the larger company ($1.57B vs $1.54B market cap).
- •Both run net losses; SNDX's is the smaller (-87.60% vs -753.60% net margin).
Metrics side by side
Valuation
| Metric | SNDX | STOK |
|---|---|---|
| P/S ratio | 6.11 | 56.82 |
| P/B ratio | 101.97 | 4.54 |
Profitability
| Metric | SNDX | STOK |
|---|---|---|
| Gross margin | 97.47% | 100.00% |
| Operating margin | -158.45% | -11.16% |
| Net margin | -87.60% | -753.60% |
| ROE | -1462.12% | -60.17% |
| ROIC | -32.15% | -63.12% |
Growth (annualized)
| Metric | SNDX | STOK |
|---|---|---|
| Revenue CAGR (5Y) | 178.06% | N/A |
| Total return CAGR (5Y) | -0.01% | -0.24% |
Frequently asked
- How have SNDX and STOK total returns compared?
- Over the past 5 years, SNDX delivered -0.01% and STOK delivered -0.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Syndax Pharmaceuticals ROEStoke Therapeutics ROESyndax Pharmaceuticals operating marginStoke Therapeutics operating marginSyndax Pharmaceuticals revenue growthStoke Therapeutics revenue growthSyndax Pharmaceuticals free cash flowStoke Therapeutics free cash flow
Syndax Pharmaceuticals & Stoke Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.